Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.

@article{Gooren2008LongtermTO,
  title={Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.},
  author={Louis J Gooren and Erik J Giltay and Mathijs C Bunck},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2008},
  volume={93 1},
  pages={
          19-25
        }
}
CONTEXT Transsexuals receive cross-sex hormone treatment. Its short-term use appears reasonably safe. Little is known about its long-term use. This report offers some perspectives. SETTING The setting was a university hospital serving as the national referral center for The Netherlands (16 million people). PATIENTS From the start of the gender clinic in 1975 up to 2006, 2236 male-to-female and 876 female-to-male transsexuals have received cross-sex hormone treatment. In principle, subjects… Expand
Long-term cross-sex hormone treatment is safe in transsexual subjects.
TLDR
It is suggested that mortality is increased among transsexuals although due to causes unrelated to cross sex replacement therapy, which will benefit the care and treatment of these subjects. Expand
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
TLDR
The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe. Expand
Long-term evaluation of cross-sex hormone treatment in transsexual persons.
TLDR
Cross-sex hormone treatment appears to be safe in transsexual men, but a substantial number of transsexual women suffered from osteoporosis at the lumbar spine and distal arm, and more attention should be paid to decrease cardiovascular risk factors during hormone therapy management. Expand
Effects of three different testosterone formulations in female-to-male transsexual persons.
TLDR
One-year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used and the detection of subtle or long-term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations. Expand
Characterization of bone mineral density in male-to-female transsexuals receiving treatment for reassignment surgery: 15 years of follow-up
TLDR
Evaluating the effect of long-term high dose estrogens, plus the antiandrogen cyproterone acetate, on bone composition and on biochemical/hormonal parameters in M2F transsexuals found cross-sex hormone treatment in male-to-female transsexuals appears reasonably safe. Expand
Management of female-to-male transgender persons: medical and surgical management, life expectancy
  • L. Gooren
  • Medicine
  • Current opinion in endocrinology, diabetes, and obesity
  • 2014
TLDR
Testosterone treatment of female-to-male transsexuals is effective and well tolerated, androgen treatment has not raised major safety concerns, and there is no increase in cardiovascular disease. Expand
Comorbidities in Transsexual Patients under Hormonal Treatment Compared to Age- And Gender-Matched Primary Care Comparison Groups
TLDR
There is no indication of an increased risk associated with HT in transsexual patients in Germany, compared to age- and gender-matched primary care patient group from the DETECT-cohort. Expand
Safety of hormonal treatment in transgenders
TLDR
Treatment must be highly individualized and transitioning patients need to be engaged in a ‘clinical contract’ with the physician in order to ensure compliance with prescribed treatments. Expand
Hormone therapy in female-to-male transgender patients: searching for a lifelong balance
TLDR
Total T, free T, and LH dosages are shown to be reliable markers of correct androgenization and the side effects and thromboembolic, metabolic, and cardiovascular risks of androgen therapy, even in the long term, appear to be irrelevant. Expand
Endocrine treatment of transsexuals: assessment of cardiovascular risk factors
  • M. Nakatsuka
  • Medicine
  • Expert review of endocrinology & metabolism
  • 2010
TLDR
In many countries, people with GID are treated according to the Standards of Care (SOC) 6th version of the World Professional Association for Transgender Health (WPATH), formerly known as the Harry Benjamin International Gender Dysphoria Association (HBIGDA) a professional organization devoted to the understanding and treatment of gender identity disorders. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Hormone Treatment of the Adult Transsexual Patient
  • L. Gooren
  • Medicine
  • Hormone Research in Paediatrics
  • 2005
TLDR
The goal of treatment in female-to-male transsexuals is to induce virilization, including a male pattern of sexual hair, a male voice and male physical contours, and to stop menses. Expand
Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.
TLDR
The range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment are discussed, as well as the potential adverse effects of cross-sex hormone treatment of transsexual people. Expand
The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals.
TLDR
The results indicate that antiandrogen and estrogen treatment in male-to-female transsexuals may suppress bone turnover and is not associated with bone loss. Expand
Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals.
TLDR
The data suggest that increased blood levels and presumably increased ovarian concentrations of testosterone may produce the morphological features of polycystic ovarian disease. Expand
Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females.
TLDR
It is concluded that tHcy levels decrease after estrogen + antiandrogen administration to male (transsexual) subjects, and levels increase after androgens administration to female (trans sexual) subjects. Expand
An epidemiological and demographic study of transsexuals in the Netherlands
TLDR
The calculated prevalence of transsexualism in The Netherlands is 1:11,900 males and 1:30,400 females, and Transsexuals live predominantly in urbanized areas, but those living in nonurbanized areas show an even distribution over the country. Expand
Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals.
TLDR
The results substantiate previous conclusions that sex reassignment is effective and clinicians need to be alert for non-homosexual male-to-females with unfavourable psychological functioning and physical appearance and inconsistent gender dysphoria reports, as these are risk factors for dropping out and poor post-operative results. Expand
The effect of androgen treatment on bone metabolism in female‐to‐male transsexuals
TLDR
The low bone turnover and preservation of trabecular bone is consistent with the assumption that testosterone treatment protects the bone in these F‐M transsexuals from the deleterious effects of estrogen deficiency and the increased cortical thickness suggests an anabolic effect of the testosterone treatment. Expand
The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.
TLDR
Findings consistent with criteria for the pathological diagnosis of polycystic ovaries, that is 3 of the 4 findings listed above, were present in 18 of the 26 subjects (69.2%). Expand
Long-term testosterone administration increases visceral fat in female to male transsexuals.
TLDR
It is concluded that long term testosterone administration in young, nonobese, female subjects increases the amount of visceral fat, and an increase in weight in this hyperandrogenic state leads to a preferential storage of fat in the visceral depot. Expand
...
1
2
3
4
5
...